109132 ⎘
Structure or type of the nucleic acid; Type of nucleic acid Antisense
ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS
#3002Antisense design
#3003Antisense design
#3004PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK
#3005Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#3006ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#3007Chiral library screen
#3008Polymers and polymeric nanogels with hydrophilics encapsulation and release capabilities and methods thereof
#3009ADIPOCYTE-SPECIFIC CONSTRUCTS AND METHODS FOR INHIBITING PLATELET-TYPE 12 LIPOXYGENASE EXPRESSION
#3010SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#3011Selective Reactivation of Genes on the Inactive X Chromosome
#3012Oligonucleotide compositions with enhanced efficiency
#3013Antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene and using method thereof
#3014Modulation of AGPAT5 expression
#3015Antisense nucleic acids
#3016Antisense-oligonucleotides as inhibitors of TGF-R signaling
#3017COMPOSITIONS AND METHODS TO CONTROL INSECT PESTS
#3018Isolated Novel Nucleic Acid and Protein Molecules from Corn and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits
#3019Modulation of prekallikrein (PKK) expression
#3020Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#3021Direct and selective inhibition of MDM4 for treatment of cancer
#3022Branched oligonucleotides
#3023Methods for characterizing alternatively or aberrantly spliced mRNA isoforms
#3024Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
#3025Anti-TNF compounds
#3026METHODS FOR TREATING EYE DISORDERS
#3027Method for controlling obesity using minimally invasive means
#3028Antisense antiviral compounds and methods for treating a filovirus infection
#3029Treatment of hormonal disorders of growth
#3030Oligonucleotide targeted to the A20-3′ untranslated region
#3031Methods and compositions for wound healing
#3032MULTIPLE EXON SKIPPING COMPOSITIONS FOR DMD
#3033Compositions and methods to control insect pests
#3034BIOLOGICAL CONTROLS OF COLEOPTERAN PESTS
#3035KRAS nucleic acids and uses thereof
#3036ANTISENSE COMPOUNDS AND USES THEREOF
#3037Antisense design
#3038Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
#3039Cancer treatment and immune system regulation through FAT10 pathway inhibition
#3040Chiral control
#3041MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
#3042Methods and compositions for preventing or reducing infections of crop plants by bacterial and fungal pathogens
#3043Methods and pharmaceutical compositions for treatment of cystic fibrosis
#3044DIAGNOSTIC AND THERAPEUTIC TARGETING OF DNMT-1 ASSOCIATED RNA IN HUMAN CANCER
#3045MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#3046Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3047ANTISENSE COMPOUNDS AND USES THEREOF
#3048Next generation RNA-sequencing and long non-coding RNA in glioblastoma multiforme
#3049POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING
#3050Tricyclo-DNA antisense oligonucleotides, compositions, and methods for the treatment of disease
#3051Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
#3052Ruthenium-based photolinkers and methods of use
#3053Bacterially derived intact minicells that encompass plasmid free DNA and methods of using the same
#3054Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#3055Allele-specific therapy for huntington disease haplotypes
#3056Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)
#3057Self-cleaving ribozymes and uses thereof
#3058Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
#3059Antisense oligonucleotides useful in treatment of Pompe disease
#3060NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#3061NUCLEIC ACID CAPABLE OF INHIBITING EXPRESSION OF BETA-2GPI
#3062ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES
#3063COMBINATORIAL TREATMENT OF CHEMOTHERAPY AND ARMED VIRUSES TARGETING TUMOR
#3064Modulation of PTPRA to treat arthritis
#3065Antibacterial antisense oligonucleotide and method
#3066COMPOSITIONS AND METHODS TO CONTROL INSECT PESTS
#3067MAP3K8 AS A MARKER FOR SELECTING A PATIENT AFFECTED WITH AN OVARIAN CANCER FOR A TREATMENT WITH A MEK INHIBITOR
#3068IMPAIRED WOUND HEALING COMPOSITION AND TREATMENTS
#3069SCN8A splice modulating oligonucleotides and methods of use thereof
#3070Modulation of breast cancer growth by modulation of XBP1 activity
#3071RAS exon 2 skipping for cancer treatment
#3072Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
#3073Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof
#3074VITAMIN K EPOXIDE RECYCLING POLYPEPTIDE VKORC1, A THERAPEUTIC TARGET OF COUMARIN AND THEIR DERIVATIVES
#3075Compositions and methods for enhancing cardiac function in the neonate
#3076BIOLOGICALLY ACTIVE NUCLEOTIDE MOLECULES FOR SELECTIVELY KILLING OFF CELLS, USE THEREOF, AND APPLICATION KIT
#3077Compositions for controlling mites in bees
#3078METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS
#3079Twist signaling inhibitor compositions and methods of using the same
#3080MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#3081Tetragalnac containing conjugates and methods for delivery of oligonucleotides
#3082Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions
#3083COMPOSITIONS AND METHODS FOR TREATING CANCER
#3084Compositions and methods for treating pancreatic cancer
#3085TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#3086PREVENTION OF TUMOUR METASTASIS BY INHIBITION OF NECROPTOSIS
#3087Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
#3088MORPHOLINOS, MORPHOLINO UPREGULATING, AND ASSOCIATED METHODS
#3089Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
#3090MicroRNA compounds and methods for modulating miR-122
#3091Peptide nucleic acid of porcine reproductive and respiratory syndrome virus and uses thereof
#3092Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
#3093Morpholino oligonucleotide manufacturing method
#3094Methods and compositions for perturbing gene expression in hematopoietic stem cell lineages in vivo
#3095ANTISENSE ANTINEOPLASTIC AGENT
#3096Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (EMT) in cancer cells
#3097Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#3098Multimetric oligonucleotide compounds
#3099COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#3100Antisense oligonucleotide compositions
#3101Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof
#3102Method for controlling obesity using minimally invasive means
#3103Oligonucleotide comprising an inosine for treating DMD
#3104Oligomers
#3105Modifications for antisense compounds
#3106Antisense nucleic acids
#3107Method for controlling obesity using minimally invasive means
#3108Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
#3109R2R1/2 in diagnosis and therapy
#3110Targeting human satellite II (HSATII)
#3111Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
#3112HCBI, MSBI, MSSI AND CMI SEQUENCES AS AN EARLY MARKER FOR THE FUTURE DEVELOPMENT OF CANCER AND DISEASES OF THE CNS AND AS A TARGET FOR THE TREATMENT AND PREVENTION OF THESE DISEASES
#3113Non-CRISPR-mediated phage resistant
#3114Antisense compounds targeting apolipoprotein E receptor 2
#3115Oligonucleotides for inducing paternal UBE3A expression
#3116Targeting the steroidogenic pathway for treating and/or preventing allergic diseases
#3117Compositions and methods for the treatment of influenza infection
#3118Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA
#3119PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
#3120TREATMENT OF LYSOSOMAL DISORDERS (IL-1 ANTAGONISTS)
#3121DD1ALPHA RECEPTOR AND USES THEREOF IN IMMUNE DISORDERS
#3122Exosomal loading using hydrophobically modified oligonucleotides
#3123SMALL RNAs (sRNA) THAT ACTIVATE TRANSCRIPTION
#3124Polynucleotide agents targeting complement component C5 and methods of use thereof
#3125Use of miR-199a-5p, targets and/or inhibitors thereof for the diagnosis, prognosis and treatment of fibroproliferative disorders
#3126Compositions and uses for treatment thereof
#3127Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
#3128INHIBITING OR DOWNREGULATING GLYCOGEN SYNTHASE BY CREATING PREMATURE STOP CODONS USING ANTISENSE OLIGONUCLEOTIDES
#3129MULTIPLE OLIGONUCLEOTIDE MOIETIES ON PEPTIDE CARRIER
#3130Antisense compounds
#3131COMPOSITIONS AND METHODS FOR THE SUPPRESSION OF TARGET POLYNUCLEOTIDES FROM LEPIDOPTERA
#3132Exon skipping technology in VCP disease
#3133Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
#3134Compositions and methods for decreasing tau expression
#3135Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
#3136Compositions for modulating Ataxin 2 expression
#3137Methods for modulating Ataxin 2 expression
#3138PERSONALIZED TREATMENT OF CANCER USING FGFR INHIBITORS
#3139LONG NON-CODING RNA AS A DIAGNOSTIC AND THERAPEUTIC AGENT
#3140Compositions and methods for modulating growth hormone receptor expression
#3141COMPOSITIONS AND METHODS FOR TARGETING O-LINKED N-ACETYLGLUCOSAMINE TRANSFERASE AND PROMOTING WOUND HEALING
#3142Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3143Methods for the treatment of cardiovascular fibrosis
#3144METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA
#3145COMPOSITION OF LIPID-BASED NANOPARTICLES FOR SMALL MOLECULES AND MACROMOLECULES
#3146ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#3147Compositions and methods for modulating complement factor B expression
#3148Antisense oligonucleotides for the treatment of Usher syndrome type 2
#3149SPLICE-REGION ANTISENSE COMPOSITION AND METHOD
#3150Reducing nonsense-mediated mRNA decay
#3151Methods of treating fragile X syndrome and related disorders
#3152Method for increasing the activity of a cystic fibrosis transmembrane conductance regulator protein
#3153Treatment of amyotrophic lateral sclerosis
#3154Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#3155COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#3156Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
#3157Combination of Anti-Clusterin Oligonucleotide with HSP90 Inhibitor for the Treatment of Prostate Cancer
#3158Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
#3159Cancer treatment
#3160COMPOSITIONS FOR INHIBITING NLRP3 GENE EXPRESSION AND USES THEREOF
#3161Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
#3162Method of promoting bone growth by an anti-actriia antibody
#3163METHODS OF TREATING CANCER USING TIGIT INHIBITORS AND ANTI-CANCER AGENTS
#3164Compositions and methods for treating ewing sarcoma
#3165Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
#3166Double-stranded oligonucleotides
#3167Nucleic acid functionalized nanoparticles for therapeutic applications
#3168Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
#3169Method for fine-tuning gene expression levels using synthetic regulatory SRNA
#3170Modified oligonucleotides for telomerase inhibition
#3171LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF
#3172Small molecules that enhance the activity of oligonucleotides
#3173Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
#3174Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels
#3175Methods and compositions for modulating apolipoprotein (a) expression
#3176Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
#3177Method for treating kidney disease with a SLIT2-binding extracellular domain of ROBO2
#3178REGULATION OF NITRATE UPTAKE AND NITROGEN USE BY BTB GENES
#3179Serpina1 iRNA compositions and methods of use thereof
#3180Modulation of growth hormone receptor expression and insulin-like growth factor expression
#3181Pharmaceutical composition for treating chronic kidney disease
#3182Antisense compositions and methods of making and using same
#3183RNA MOLECULES AND USES THEREOF
#3184METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#3185Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)
#3186METHODS OF USING GAP JUNCTIONS AS THERAPEUTIC TARGETS FOR THE TREATMENT OF DEGENERATIVE DISORDERS OF THE RETINA
#3187p-Ethoxy nucleic acids for liposomal formulation
#3188STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases
#3189Compositions and methods for modulating dysferlin expression
#3190Modulation of gene expression and screening for deregulated protein expression
#3191Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212)
#3192PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES
#3193Diagnosis and treatment of Friedreich's ataxia
#3194Compounds and methods for enhanced cellular uptake
#3195Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
#3196ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
#3197AGENTS INHIBITING GRANULIN FOR TREATMENT OF CANCER
#3198Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
#3199COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
#3200Methods for Inhibiting Epithelial to Mesenchymal Transition by Inhibition of FOXS1
#3201Method of Modulating Fibroblast Accumulation or Collagen Deposition
#3202Targeting hepatitis B virus (HBV) host factors
#3203Retinoid-lipid drug carrier
#3204MODULATORS OF GROWTH HORMONE RECEPTOR
#3205Modulation of TMPRSS6 expression
#3206Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#3207Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
#3208SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION
#3209METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA
#3210Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
#3211Antisense treatment of radiation induced diseases in the gastrointestinal tract
#3212Method of treatment of chlamydial infections with selected EGFR inhibitors
#3213Methods for preventing and treating chronic kidney disease (CKD)
#3214Antisense nucleic acids
#3215Antisense nucleic acids
#3216METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING IL-27 INDUCED PATHWAYS
#3217TREATMENT OF RESISTANT LESIONS
#3218Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#3219Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
#3220EXTRACELLULAR VESICLE METHODS AND COMPOSITIONS
#3221Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
#3222ANTISENSE OLIGOMERS AND METHODS FOR TREATING SMN-RELATED PATHOLOGIES
#3223P97-polynucleotide conjugates
#3224OLIGONUCLEOTIDE SPECIFIC UPTAKE OF NANOCONJUGATES
#3225Compositions and methods to promote erythropoiesis
#3226Oligomeric compounds comprising alpha-beta-constrained nucleic acid
#3227Compositions and Methods for Modulation of SMN2 Splicing in a Subject
#3228METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#3229Methods for the treatment of Leber congenital amaurosis
#3230Methods for producing enteroendocrine cells that make and secrete insulin
#3231Linkage modified oligomeric compounds
#3232Methods for treating T-cell acute lymphoblastic leukemia
#3233Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
#3234Compositions for modulating SOD-1 expression
#3235MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#3236Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#3237SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE
#3238Polycomb-associated non-coding RNAs
#3239Methods for treating and/or limiting development of diabetes
#3240Use of annexin A3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma
#3241MODULATION OF FACTOR 11 EXPRESSION
#3242Oligonucleotide analogues incorporating 5-aza-cytosine therein
#3243Sterile Emulsion Comprising a Stable Phosphorothioate Oligonucleotide
#3244Recombinant virus products and methods for inhibition of expression of DUX4
#3245COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI)
#3246RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
#3247Agents useful in treating facioscapulohumeral muscular dystrophy
#3248Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma
#3249Oligomers
#3250METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
#3251DDX5 AND ASSOCIATED NON-CODING RNAs AND MODULATION OF TH17 EFFECTOR FUNCTION
#3252Method of Treating Cancer by Inhibition of DNA Repair Proteins
#3253COMPOSITIONS AND AGENTS AGAINST HEPATITIS B VIRUS AND USES THEREOF
#3254Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
#3255Compositions and methods for treating cachexia
#3256Compositions and methods for modulation of SMN2 splicing in a subject
#3257System of interdependent anticancer antisense oligonucleotides targeting mRNAs the targets of which are NADPH-dependent, combined with one or more inhibitors of the Pentose Phosphate Pathway to deplete NADPH
#3258RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
#3259ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#3260ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#3261COMPOSITIONS FOR INHIBITING DUX4 GENE EXPRESSION AND USES THEREOF
#3262Compositions and methods for treating diabetes
#3263Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
#3264Modulation of prekallikrein (PKK) expression
#3265Method for treatment of heart failure
#3266METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS
#3267CD300A RECEPTORS AS VIRUS ENTRY COFACTORS
#3268Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity
#3269Identification and use of target genes for control of plant parasitic nematodes
#3270Molecular re-engineering of excitation-inhibition balance in memory circuits
#3271Functionally-modified oligonucleotides and subunits thereof
#3272METHODS FOR DIAGNOSING AND TREATING MYHRE SYNDROME
#3273Modulation of NLGn4 expression, NK cell activity in non-alcoholic fatty liver disease (NAFLD)
#3274Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
#3275Modulation of transthyretin expression
#3276Compositions and their uses directed to huntingtin
#3277Methods and compositions for treating solid tumors and enhancing tumor vaccines
#3278TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF
#3279Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#3280Methods and compositions for modulating alpha-1 antitrypsin expression
#3281TREATMENT OF CARDIAC DISEASES WITH MODULATORS OF THE HIPPO PATHWAY
#3282METHODS FOR CATEGORISING CANCER SUCH AS BREAST CANCER
#3283Control of Varroa mite infestation
#3284Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#3285PROKARYOTIC RNAi-LIKE SYSTEM AND METHODS OF USE
#3286Antisense oligonucleotides for treatment of spinal muscular atrophy
#3287Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA Structure
#3288Double stranded oligonucleotide compounds comprising positional modifications
#3289Targeted therapeutic nucleosides and their use
#3290Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease
#3291Antisense design
#3292Modulation of signal transducer and activator of transcription 3 (STAT3) expression
#3293Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
#3294MODULATION OF TRANSTHYRETIN EXPRESSION
#3295Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
#3296Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
#3297Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
#3298Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
#3299Delivery of packaged RNA to mammalian cells
#3300In vitro method for identifying compounds of the Nav 1.9 sodium channel intended for the treatment of an inflammatory skin disease